We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
- Authors
Ng, Eugene W M; Shima, David T; Calias, Perry; Cunningham, Emmett T, Jr; Guyer, David R; Adamis, Anthony P
- Abstract
Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, the VEGF isoform primarily responsible for pathological ocular neovascularization and vascular permeability. After nearly a decade of preclinical development to optimize and characterize its biological effects, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Pegaptanib therefore has the notable distinction of being the first aptamer therapeutic approved for use in humans, paving the way for future aptamer applications.
- Publication
Nature reviews. Drug discovery, 2006, Vol 5, Issue 2, p123
- ISSN
1474-1776
- Publication type
Journal Article
- DOI
10.1038/nrd1955